focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBARK.L Regulatory News (BARK)

  • There is currently no data for BARK

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Company Update and Issue of Equity

30 Sep 2020 07:00

RNS Number : 5114A
Barkby Group PLC (The)
30 September 2020
 

30 September 2020

The Barkby Group PLC

("Barkby", the "Group" or the "Company")

Company Update and Issue of Equity

 

The Barkby Group PLC, the diversified business group, announces the following update.

 

Board change

Following the appointment of Douglas Benzie as Chief Financial Officer in March, Emma Dark has formally stepped down as a Director and Company Secretary of the Group. Emma will continue to support the Group finance function in a non-statutory role. Emma has led the finance function of the Group since its inception. The Board would like to thank Emma for her contribution to the Group, particularly her significant role in the acquisition that completed earlier this year.

 

Deferred consideration amendment

Barkby and Turf to Table Ltd have agreed an amendment to the deferred consideration due to Turf to Table relating to Barkby's acquisition of pub assets and trade in 2018.

 

Barkby will now pay £115,000 in lieu of the balance of existing deferred consideration of £150,000. £60,000 of the outstanding £115,000 due will be satisfied by the issue and allotment of 260,869 ordinary shares in the capital of Barkby ("Ordinary Shares") at a price of 23 pence per Ordinary Share, and the balance of £55,000 is payable in cash no later than 30 September 2020. The amendment to the original terms will conserve £95,000 of cash for the Group.

 

Issue of Equity

Barkby has applied to the London Stock Exchange for 260,869 Ordinary Shares to be admitted to trading on AIM ("Admission"). It is expected that Admission will become effective and trading will commence in the new Ordinary Shares at 8.00 a.m. on 1 October 2020. On Admission the Company's issued share capital will comprise 135,495,935 Ordinary Shares, of which none are held in treasury. Therefore the total number of Ordinary Shares in the Company with voting rights will be 135,495,935. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.

 

Planning permission granted

Further to the trading update of 22 July 2020, which announced that Barkby had secured planning permission from Wellingborough Borough Council to build a 20,000 sq. ft. mixed use retail and trade scheme, Barkby has now acquired part of the site for a modest sum. Barkby will add finance against the freehold site, before the scheme is forward funded by a purchaser. Construction is expected to begin in 2021.

 

 

 

Enquiries:

 

The Barkby Group PLC

Charles Dickson, Executive Chairman

Douglas Benzie, Chief Financial Officer

finnCap Ltd (Nomad and Broker)

+44 (0) 20 7220 0500

Carl Holmes/Simon Hicks (corporate finance)

Tim Redfern/Richard Chambers (ECM)

 

Camarco (Financial PR)

+44 (0) 20 3757 4994

Jennifer Renwick/Jake Thomas

Notes to editors

The Barkby Group PLC is a diversified group of high growth, high quality businesses run by an entrepreneurial and experienced management team. The existing wholly owned businesses within Barkby include; Commercial Property Development, Barkby Life Sciences, Barkby Hospitality (comprising Barkby Pubs and Workshop Coffee) and Centurian Automotive. Barkby's strategy is to accelerate and maximise opportunities within its existing businesses as well as continue to source and invest in cash generative, growth businesses with the ability to disrupt.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCLLMMTMTATTTM
12
Date   Source Headline
30th Jan 20246:03 pmRNSChange of Name to Roadside Real Estate plc
2nd Jan 20247:00 amRNSResult of General Meeting
19th Dec 202311:15 amRNSUpdate on debt refinancing and CSS
15th Dec 20237:00 amRNSFirst joint venture acquisition
13th Dec 20235:39 pmRNSPosting of Circular and Notice of General Meeting
4th Dec 20237:00 amRNSIntention to refinance debt facilities
7th Nov 20237:00 amRNSPractical completion of second Roadside asset
31st Oct 20237:00 amRNSFormation of Roadside Real Estate Joint Venture
29th Sep 20237:00 amRNSTrading update
19th Sep 20237:00 amRNSCSS Announces Licensing Deal with Mammoth
11th Sep 20237:00 amRNSResponse to media speculation re CSS
1st Aug 20237:00 amRNSDisposal of Workshop Coffee
14th Jun 20237:42 amRNSCSS announces new licensing agreement
9th Jun 20237:00 amRNSPub portfolio update
6th Jun 20237:00 amRNSMajor licensing deal for Cambridge Sleep Sciences
31st May 20237:00 amRNSPractical completion of first Roadside asset
15th May 20237:00 amRNSBoard Update, Equity Issue & Total Voting Rights
31st Mar 20237:00 amRNSInterim results
22nd Feb 20235:26 pmRNSResult of AGM
16th Jan 20237:00 amRNSNotice of AGM & Debt Facility Drawing
30th Dec 20227:01 amRNSFinal results for the year ended 2 July 2022
30th Dec 20227:00 amRNSRevised debt facility
28th Nov 20227:00 amRNSTrading and Strategy Update
25th Nov 20227:00 amRNSAcquisition of the Eliot Arms
7th Sep 20225:48 pmRNSHolding(s) in Company
18th Jul 20227:00 amRNSTrading and Strategy Update
21st Jun 20223:19 pmRNSDirector/PDMR Shareholding
11th May 20225:21 pmRNSHolding(s) in Company
26th Apr 20227:00 amRNSExchange of Contracts at Saffron Walden, Essex
1st Apr 20227:00 amRNSAcquisition of The Coach and Horses
30th Mar 20227:20 amRNSInterim Results
4th Mar 20226:09 pmRNSHolding(s) in Company
3rd Mar 20227:00 amRNSAppointment of Group Property Director
2nd Mar 20227:00 amRNSVerso Biosense completes clinical study
1st Mar 20227:00 amRNSBoard Update
8th Feb 20225:35 pmRNSResult of AGM
3rd Feb 20223:33 pmRNSIssue of Equity and Total Voting Rights
25th Jan 20227:00 amRNSCambridge Sleep Sciences Announces New Partners
18th Jan 20227:00 amRNSVerso Biosense study nears completion
13th Jan 20227:00 amRNSPosting of Annual Report & Notice of AGM
24th Dec 20217:00 amRNSFinal Results for the Year Ended 1 July 2021
20th Dec 20212:06 pmRNSSecond Price Monitoring Extn
20th Dec 20212:00 pmRNSPrice Monitoring Extension
17th Dec 20217:00 amRNSExchange of Contracts in Swindon, Wiltshire
27th Oct 20214:41 pmRNSSecond Price Monitoring Extn
27th Oct 20214:35 pmRNSPrice Monitoring Extension
27th Oct 20212:05 pmRNSSecond Price Monitoring Extn
27th Oct 20212:00 pmRNSPrice Monitoring Extension
27th Oct 202111:05 amRNSSecond Price Monitoring Extn
27th Oct 202111:00 amRNSPrice Monitoring Extension
12

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.